Via EFS Attorney Docket No.: 16534-539001US

Date of Deposit: April 2, 2010

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Levy, et al. CONFIRMATION NO. 8952

SERIAL NO.: 10/692,764 EXAMINER: Janet L. Epps-Smith

FILING DATE: October 24, 2003 ART UNIT: 1633

FOR: METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO

Modulate RNA

## Mail Stop RCE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## **AMENDMENT AND RESPONSE**

This paper is submitted in response to the Advisory Action mailed on March 11, 2010 ("Advisory Action") and further in response to the Final Office Action mailed on December 22, 2009 ("Final Office Action"), in the above-identified patent application. With a Petition for a One-month Extension of Time, a Response is due on or before April 22, 2010.

Applicants submit this paper in conjunction with a Request for Continued Examination under 37 C.F.R. §1.114 and the fee required under 37 C.F.R. §1.17(e). This paper constitutes a proper submission under 37 C.F.R. §1.114(c).

Applicants have included an information disclosure statement (IDS) herewith. Applicants believe no fee is due because the IDS is being filed concurrently with an Request for Continued Examination, pursuant to 37 C.F.R. 1.97(b)(4).

Applicants believe no additional fees are due, however, the Commissioner is hereby authorized to charge any such additional fee(s), or to credit any overpayment, to Deposit Account No. 50-0311, Reference No. 16534-539001US, Customer Number: 30623.

Amendments to the Claims begin on page 2.

Remarks/Arguments begin on page 51.